Literature DB >> 21271584

The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis--an effective therapy.

Gauthier Desuter1, Thierry Duprez, Caroline Huart, Quentin Gardiner, Gust Verbruggen.   

Abstract

This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor-alpha (TNF-α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis-related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF-α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271584     DOI: 10.1002/lary.21343

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  FDG-PET/CT can rule out malignancy in patients with vocal cord palsy.

Authors:  Anders Thomassen; Anne Lerberg Nielsen; Jeppe Kiilerich Lauridsen; Björn Alexander Blomberg; Søren Hess; Henrik Petersen; Allan Johansen; Jon Thor Asmussen; Jesper Roed Sørensen; Jørgen Johansen; Christian Godballe; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

2.  Evaluation of the Swallowing and Voice Functions in Ankylosing Spondylitis Patients.

Authors:  Esmail Abdulahi Ahmed; Sevgi Atar; Yavuz Atar; Hüseyin Sari; Melis Ece Arkan Anarat; Ziya Saltürk; Seyma Görcin Karaketir; Yavuz Uyar; Ömer Kuru
Journal:  Dysphagia       Date:  2021-07-14       Impact factor: 3.438

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.